Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 9/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | AKT2 | P31751 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 4/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.34 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12370985 | 0.76 | PTGS2 (0.40) | ADORA1ADORA2A | |
| SCHEMBL12370988 | 0.76 | ADORA1 (0.38) | ADORA1ADORA2AADORA2B | |
| SCHEMBL28762490 | 0.76 | CYP11B1 (0.43) | KDM1ACYP11B1CYP11B2 | |
| SCHEMBL1351892 | 0.71 | AKT1 (0.46) | AKT1AKT2 | |
| SCHEMBL1350052 | 0.71 | AKT1 (0.48) | AKT1AKT2 | |
| SCHEMBL3597677 | 0.70 | MEN1 (0.48) | KDM1AMAOB | |
| SCHEMBL1352411 | 0.68 | CCNB2 (0.39) | AKT1AKT2 | |
| SCHEMBL17111483 | 0.67 | ADORA1 (0.53) | ADORA1ADORA2AADORA2B | |
| SCHEMBL2281711 | 0.66 | GSK3B (0.39) | ADORA1ADORA2AAKT1AKT2 | |
| SCHEMBL30358225 | 0.65 | CCNB2 (0.44) | KDM1ACYP11B1CYP11B2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003643-B2 | Inhibitors of Akt activity | MERCK SHARP & DOHME CORP. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20100075970-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. | 2010-03-25 | — | — | US | disclosed |
| US-7655649-B2 | Cancer; N,N-dimethyl-5-phenyl-6-(4-{[4-(5-pyridin-2-yl-1H-pyrazol-3-yl)piperidin-1-yl]methyl}phenyl) pyridazin-3-amine;; serine/threonine kinase (Akt) suppression; increased cellular potency or solubility, enhanced pharmacokinetic properties | MERCK SHARP & DOHME CORP. (US) | 2010-02-02 | — | — | US | disclosed |
| EP-1737843-A4 | INHIBITORS OF AKT ACTIVITY | MERCK & CO INC (US) | 2009-01-28 | — | — | EP | disclosed |
| US-20080280889-A1 | Inhibitors of Akt Activity | MERCK SHARP & DOHME CORP. | 2008-11-13 | — | — | US | disclosed |
| CN-1942465-A | Inhibitors of AKT activity | MERCK & CO INC (US) | 2007-04-04 | — | — | CN | disclosed |
| EP-1737843-A1 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005100344-A1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075970-A1 | INHIBITORS OF AKT ACTIVITY | PIK3CA, AKT2, AKT1 | ADORA1 2477/4885ADORA2A 1430/4885AKT1 3/4885 |
| US-20080280889-A1 | Inhibitors of Akt Activity | AKT2, PIK3CA, AKT1 | ADORA1 2299/4885ADORA2A 1322/4885AKT1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.